Holen Sie sich die Stockscreener-App
228.35
0.37%
-0.84
Vorhandelsmarkt:
228.31
-0.04
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$229.19
Offen:
$225.91
24-Stunden-Volumen:
837.61K
Relative Volume:
0.58
Marktkapitalisierung:
$32.94B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
22.01
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
-4.98%
1M Leistung:
+2.33%
6M Leistung:
-11.85%
1J Leistung:
-16.60%
1-Tages-Spanne:
$225.12
$228.49
1-Wochen-Bereich:
$225.12
$242.40
52-Wochen-Spanne:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
228.35 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
366.70 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
184.74 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.50 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.59 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Wellington Management Group LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC - MarketBeat
ResMed Inc. stock heads into the open after a 0.4% dip - AD HOC NEWS
Why Is ResMed Inc. (ASX:RMD) Drawing Fresh Attention Among Healthcare Stocks? - Kalkine Media
How is ResMed (ASX:RMD) framing its sleep research push? - Kalkine Media
ResMed Inc. stock gains on FY2026 growth and buyback launch - AD HOC NEWS
ResMed Inc Reports August 2026 CHESS Depositary Interests and Securities Update - Kalkine Media
Paralel Advisors LLC Purchases Shares of 10,293 ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc. - MarketBeat
ResMed Inc Discloses August 2026 CDI and Securities Statement - Kalkine
Why Is ResMed (ASX:RMD) Sustaining Home-Care Demand? - Kalkine Media
ResMed Director Peter Farrell Sells 970 Shares Under Rule 10b5-1 Plan - Kalkine
ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentimen - AD HOC NEWS
ResMed Director Peter Farrell Executes Sale of 970 Shares via 10b5-1 Trading Plan - Kalkine Media
ResMed chairman emeritus Peter Farrell sells $227,688 in stock By Investing.com - Investing.com South Africa
ResMed (NYSE:RMD) Director Peter Farrell Sells 970 Shares - MarketBeat
ResMed (RMD) director sells shares under trading plan - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc.RMD - PR Newswire
Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating - marketscreener.com
Nykredit A S Acquires New Position in ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts - ChartMill
Jupiter Topco LLC Takes Position in ResMed Inc. $RMD - MarketBeat
Director at ResMed (NYSE: RMD) plans new 970-share stock sale - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,064 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Van ECK Associates Corp - MarketBeat
ResMed (RMD) Announces $450 Million Accelerated Share Repurchase Agreement - GuruFocus
ResMed Enters $450 Million Accelerated Share Repurchase Agreement With Citibank; Shares Fall 3% - moomoo.com
Is ResMed Inc (RMD) a Bargain After 3.6% Drop? GF Value Says Und - GuruFocus
ResMed Launches $450 Million Accelerated Share Buyback With Citibank - marketscreener.com
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
ResMed (NYSE: RMD) plans to use MatrixCare sale cash for fast-track buyback - Stock Titan
Resmed Inc Stock (RMD) Moved Down by 3.25% on Sep 1: Facts Behind the Movement - TradingKey
Frazier Healthcare completes acquisition of MatrixCare from ResMed By Investing.com - Investing.com South Africa
MatrixCare software serves more than 15,000 providers. Frazier completes the acquisition. - Stock Titan
Quantitative Investment Management LLC Invests $2.21 Million in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stock Position Raised by Railway Pension Investments Ltd - MarketBeat
Public Employees Retirement System of Ohio Takes $9.75 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Rating of "Hold" by Brokerages - MarketBeat
ResMed Unlocks A Bigger Sleep-Health Ecosystem With OURA And Noctrix! - Smartkarma
Frazier Management, L.L.C. completed the acquisition of MatrixCare, Inc. from ResMed Inc.. - marketscreener.com
KeyBanc raises ResMed stock price target on FY27 outlook confidence - Investing.com
Rakuten Investment Management Inc. Takes Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Navigating Growth with 8.6% Revenue Surge and Promising 2.15% Upside - DirectorsTalk Interviews
KeyBanc Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $267 - Moomoo
Manulife buys $14.4M ResMed stake as revenue climbs 8.6% - Dealroom
GTS Securities LLC Has $2.05 Million Holdings in ResMed Inc. $RMD - MarketBeat
United Capital Financial Advisors LLC Purchases New Holdings in ResMed Inc. $RMD - MarketBeat
Freestone Grove Partners LP Invests $1.52 Million in ResMed Inc. $RMD - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in ResMed Inc. $RMD - MarketBeat
Corient Private Wealth LP Purchases Shares of 85,266 ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):